There is a preference for the use of disease-modifying therapies
that are associated with a lower risk of infection, such
as interferons, glatiramer acetate, teriflunomide, and natalizumab. Additionally, extended-interval dosing
of natalizumab is favored when it is considered safe for
the patient.